

Genetic and epigenetic alterations of GNAS locus and clinical consequences in Pseudohypoparathyroidism: a new health care pathway

F Giachero^{1,3}, FM Elli², M Baricco^{1,3}, P Matarazzo³, G Mantovani², L de Sanctis^{1,3}

¹ Department of Public Health and Pediatrics, University of Turin, 10126 Turin, Italy.
² Endocrinology and Diabetology Unit, University of Milan, Fondazione Ospedale Maggiore Policlinico Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 20122 Milan, Italy.
³ Regina Margherita Children's Hospital, 10126 Turin, Italy.

Background

Genetic and epigenetic alterations at the GNAS locus are responsible for the G α s protein dysfunctions causing Pseudohypoparathyroidism (PHP), a heterogeneous disease characterized by multiple hormone resistances and AHO signs (short stature, obesity, round face, brachydactyly, subcutaneous ossifications and mental retardation). A clinical overlap among molecular subtypes of the disease (Ia, Ib, Ic and II) makes the current classification inadequate; furthermore a common clinical approach still needs to be defined.

- * Lack of knowledge about some clinical features and their evolution
- * No common standards in clinical management
- * New Classification required

Aims and Objective

In the largest Italian case series of (epi)/genetically characterized PHP patients, this work attempts to review and update the clinical data, correlating them to the molecular diagnosis, and to develop a healthcare pathway for patients with AHO/PHP.

Cooperating Network of ISPED Centers - Study Group *Endocrine diseases due to altered function of G α s protein*


Review of clinical data of patients with confirmed molecular diagnosis

Collection of new follow-up data

Develop and share a **new health care pathway**

Common clinical approach to **DIAGNOSIS, THERAPY and FOLLOW-UP**

Materials and Methods




74 patients with confirmed molecular diagnosis
from 69 unrelated families


- 46 GNAS gene mutations
- 28 GNAS locus altered methylation

Results


AUXOLOGICAL EVALUATION




Clinical Features - Overview





HORMONE RESISTANCES



Mutation prevalence among pts with SO




Cognitive Areas involved in MR



Conclusions

A dedicated healthcare pathway addressing all the PHP's aspects in a systematic way would improve the management of the disease, allowing an earlier diagnosis of hormonal resistances, which is fundamental to optimize the medical treatment (i.e. rGH therapy). On the other hand, the different prevalence and features of some AHO signs need to be confirmed by follow-up data, leading thus to a better clinical-oriented molecular analysis.



The authors have nothing to disclose

